Gayatin, Krizzia Jane P.
HRN: 19-92-03 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/18/2022
CEFUROXIME 500MG (TAB)
10/18/2022
10/25/2022
ORAL
500mg
Q12
S/P Pelvic Lap
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes